C-reactive protein (CRP) is an important indicator of inflammatory conditions and increased risk for cardiovascular disease. The association between CRP and HIV is still uncertain. This study describes the longitudinal evaluation of plasma CRP in patients initiated on dolutegravir (DTG) based antiretroviral regimen. 